Robert Wood Johnson University Hospital Somerset

Summary

Robert Wood Johnson University Hospital Somerset is a medical facility located in Somerville, New Jersey. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer, Colon Cancer and other specialties. Robert Wood Johnson University Hospital Somerset is involved with conducting 120 clinical trials across 147 conditions. There are 15 research doctors associated with this hospital, such as Howard S. Hochster, Eugenia Girda, MD, Missak Haigentz, MD, and Mridula George, MD.

Top PIs

Clinical Trials running at Robert Wood Johnson University Hospital Somerset

Breast Cancer

Ovarian Cancer

Lung Cancer

Breast cancer

Bladder Cancer

Prostate Cancer

Colon Cancer

Uterine Cancer

Small Cell Lung Cancer

Cancer

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria